These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 15246845)

  • 1. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
    Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
    Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity.
    Darvesh S; MacDonald SE; Losier AM; Martin E; Hopkins DA; Armour JA
    J Auton Nerv Syst; 1998 Jul; 71(2-3):75-84. PubMed ID: 9760044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
    Loewenstein Y; Gnatt A; Neville LF; Soreq H
    J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
    Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
    Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J
    Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus.
    Darvesh S; Hopkins DA
    J Comp Neurol; 2003 Aug; 463(1):25-43. PubMed ID: 12811800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of cholinesterase in two snails Pila globosa and Lymnaea acuminata.
    Singh DK; Singh O; Agarwal RA
    J Physiol (Paris); 1982; 78(5):467-72. PubMed ID: 7184992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
    Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
    Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
    Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
    Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase.
    Berman HA; Leonard K
    Mol Pharmacol; 1992 Feb; 41(2):412-8. PubMed ID: 1538717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
    Giacobini E
    Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.